High-titer, purified herpes simplex virus thymidine kinase (HSV-TK) retroviral particles, followed with intraperitoneal ganciclovir (GCV) were tested in Fischer rats bearing 1-week established 9L gliosarcomas. 9L cells were infused intracranially through a cannula on day 0, given intracranial infusions of HSV-TK retroviral particles on days 7-12, and given 5 or 10 daily doses of intraperitoneal GCV starting at day 14. Tumor volumetric studies performed on rat brains at day 26 after tumor infusion revealed significant differences in experimental groups receiving HSV-TK retroviral particles plus 10-day GCV or the 100% transduced 9L-TK group receiving GCV versus control groups treated with either buffer, HSV-TK vector, or either 5-or 10-day regimens of GCV alone. The duration of GCV administration and the volume of tumor burden influenced efficacy. Adjuvant dexamethasone did not significantly affect efficacy. Experiments in which 9L rechallenge of animals treated with 9L-TK/GCV or 9L tumors treated with HSV-TK vector/GCV indicated that a host immune response was involved in rejecting the rechallenge tumor. Outcome was dependent upon the site and size of the rechallenge inoculum. In vitro, bystander effects were significant but were especially marked when cell-to-cell contact was maintained. Cumulatively, the data indicate that both the bystander effect and the host immune response are responsible for the efficacy observed in the suicide gene therapy paradigm using purified HSV-TK retroviral particles and GCV to treat smaller tumor burden in rats with 9L gliosarcoma.
H uman glial neoplasms are among the most resistant tumors to conventional antineoplastic therapy. Although surgery, cranial radiation, and chemotherapy can reduce overall tumor burden, none successfully eradicate the malignancy. 1 Recurrence of primary central nervous system tumors is usually the result of individual infiltrative tumor cells left at the periphery of the mass lesion. To eliminate the small groups of infiltrating cells that diffuse away from the main tumor mass, adjuvant immunotherapy and gene therapy strategies are being explored with the hope that these infiltrating cells can be targeted. [2] [3] [4] Two factors that will greatly facilitate clinical application of retroviral-mediated human gene transfer are the development of high-titer retroviral preparations and those that are free of detectable replication-competent retroviruses. In a previous communication, we reported the development of vector constructs that possess these two features. 5 These replication-defective, highly purified retroviral vector particles, tested in the suicide gene therapy of experimental 9L brain tumors, resulted in cured animals with histological features consistent with the formation of a sterile abscess at the site of tumor instillation without significant damage to adjacent brain. In animals with viable tumors, large numbers of CD4 ϩ and CD8 ϩ lymphocytes infiltrated the residual tumor. In the current report, we (a) quantitatively characterize the efficacy of the retroviral particles and antiviral treatment using established 9L gliosarcomas in rats with low and high tumor burdens, (b) explore the effects of major clinical variables such as dexamethasone (Dex) and the duration of ganciclovir (GCV) administration on the efficacy of the treatment, (c) report the in vitro analysis of the bystander effect, (d) examine the humoral response to the treatment, and (e) present more evidence on the cell-mediated effects by presenting 9L tumor rechallenge data when tumor is administered intracranially (i.c.) or systemically (sys) to animals that have undergone prior suicide gene therapy.
MATERIALS AND METHODS

Vector preparation
Details of the construction of the murine herpes simplex virus thymidine kinase (HSV-TK) retroviral provector, the method used to generate retroviral packaging cell lines that minimizes the formation of replication-competent retrovirus, and the method used to produce a high-titer amphotropic vector involving selection, dilution cloning, and screening are as described previously. 5 The expansion of the high-titer producer clones in 85,000-cm 2 Cell Cube TM culture vessels (Corning CoStar, Cambridge, Mass) and their concentration by tangential flow ultrafiltration are also described in more detail. 5 Cell culture 9L gliosarcoma cells were cultured in RPMI 1640:Dulbecco's modified Eagle's medium (2:1 vol/vol, BioWhittaker Biologicals, Walkersville, Md) containing 10% fetal calf sera (Life Technologies, Grand Island, NY), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 M nonessential amino acids, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (pH 7.2). 9L-TK cells were selected in medium containing G418 (400 g/mL effective concentration).
Quantitative in vitro assay for bystander killing using parental and HSV-TK-transduced 9L cells and GCV Parental 9L cells were admixed with 100% HSV-TK-transduced 9L cells at various percentages (0, 1, 2, 5, 10, 20, 40, 60, 80, and 100%). The mixtures were seeded in triplicate at a total of 3 ϫ 10 4 cells/well into a 96-well tissue culture plate and grown overnight; another set of cell mixtures was plated, but at a 1/20 dilution of the above cell concentration. The first set of cell admixtures plated at higher concentration was used to measure cumulative 9L cell killing by GCV and bystander effects; the lower concentration of cells in the second plate was used to measure largely 9L cell killing by GCV alone. The cells were then exposed to GCV-containing medium at a concentration of 10 g/mL for 24 hours. The medium was aspirated, and the monolayers were washed once with phosphate-buffered saline (PBS) solution, trypsinized, washed with fresh complete medium prewarmed to 37°C, split 1:10, and cultured for 5 days. Relative metabolic activity was then estimated using a CellTiter 96 AQ kit (Promega, Madison, Wis) according to the manufacturer's instructions. This colorimetric cell proliferation assay measures viable cell dehydrogenase activity.
Infusion of tumor and gene therapy treatment
Tumor cells were infused i.c. through a stainless steel cannula permanently implanted in the right parietal lobe 6 of viral antigen-free male Fischer rats weighing between 200 and 250 g (Sasco, Madison, Wis). Either parental 9L or fully HSV-TKtransduced, G418-selected 9L-TK gliosarcoma cells (5,000 or 10,000 cells, dependent upon the experiment, suspended in 10 L of Hank's balanced salt solution) were infused on day 0. Six daily i.c. infusions of retroviral particles (10 8 colony-forming units (cfu)/mL, 10 L) into parental 9L tumors commenced on day 7. Either 5 or 10 (dependent upon experiment) daily intraperitoneal (i.p.) injections of GCV (50 mg/kg) began on day 14. The experimental regime is diagrammatically illustrated, and the control and experimental animal groups are as described elsewhere. 5 Negative control groups with parental 9L were either sham-treated, HSV-TK retroviral particletreated, or GCV-treated in the time frame given. 5 Formulation buffers or saline were substituted when active agent was not given. A positive control group was given 9L-TK and 10 days of GCV. In an experiment investigating the effects of Dex on suicide gene therapy, oral Dex was given to the rats (0.06 mg/20 mL drinking water) starting on day 6 and continued through day 20, at which time tapering was initiated. Every 2 days, the concentration of steroid was reduced from 0.06 to 0.045 to 0.03 to 0.015 to 0 mg per 20 mL.
Tumor volumetric analyses of control animals and animals treated with suicide gene therapy at day 26 after 9L infusion
Tumor volumetric analyses were performed on all groups of animals at day 26 after 9L infusion. Rats were sacrificed by CO 2 overdose. Whole brains were removed from the skull, placed into a Jacobowitz rat brain slicer (Zivic Miller, Allison Park, Penn), and chilled for 5 minutes at Ϫ20°C; next, two coronal slices were made, one at the site of cannula implantation and tumor infusion and the other 4 mm posterior to the cannula. For paraffin embedding, the two 4-mm sections anterior and posterior to the cannulation site were placed into a tissue cassette and put into buffered formalin for fixation.
Five sections (5 m) taken at the tumor instillation site and at 250-m intervals out to 1000 m (covering 2000 m total saggital distance) were placed onto polylysine-coated slides and stained with Harris hematoxylin and eosin. Slides were placed into a photographic enlarger, and the images (at ϫ3 magnification) were projected so that the total brain and total tumor areas could be traced by two-dimensional mapping. Using Sigma-Scan software (SPSS Inc., Chicago, Ill), a scanspecific formula based on the magnification factor was applied for deriving brain and tumor areas. An additional formula calculated the percent tumor volume to total brain volume within the total thickness of the sections measured; an assumption was made that the tumor projected in a conical shape from the site of instillation, which was assumed to be the site with the greatest diameter of tumor.
Survival analyses of control and suicide gene therapytreated animals
In one experiment, the survival of animals treated with vector only or with vector and GCV was calculated at 60 days after the infusion of 9L tumor (5000 cell inoculum established in 1 week). Kaplan-Meier survival plots were devised as explained previously. 7 Mean survival times (MSTs) were calculated by Mantel-Haenzel nonparametric log-rank and Wilcoxon tests. Any surviving animals at day 60 were rechallenged with parental 9L cells (10 5 ) intramuscularly (i.m.) in the right leg. Animals were sacrificed 2 weeks later. Brains were removed and fixed in buffered formalin, and 4-mm sections surrounding the cannula site were embedded in paraffin. Other tissues were collected for histology also. Sections (5 ) were stained with hematoxylin and eosin.
In another experiment designed to explore the effects of higher tumor burden and Dex therapy on suicide gene therapy efficacy, the tumor inoculum was doubled (10,000 9L cells established in 1 week) and Dex (drinking water concentration ϭ 0.003 mg/mL) was added to several experimental groups. Steroid began 1 day before vector administration and continued at that dose until day 20, when tapering began; by day 26, the animals were weaned from steroid.
Assessment of treatment toxicity
Animals were observed daily for evidence of gross neurological abnormalities. In addition, animals were weighed every 2-3 days, and weights were plotted over the treatment period as an assessment of treatment toxicity. One indication of toxicity to treatment is a significant weight drop (Ͼ20%) during the administration of treatment agent. 6 
Rechallenge experiments
Animals were either (a) administered 9L-TK i.c. (10 L) or systemically (i.m. hind limb, 0.1 mL) followed by a 10-day regimen of i.p. GCV (days 14 -23 posttumor) at 50 mg/kg, or (b) given 9L tumor, which was transduced in situ with six daily i.c. infusions of HSV-TK vector (6 ϫ 10 6 cfu), and then given the 10-day regimen of GCV. Rechallenge with parental 9L cells occurred on either day 28 or day 60 after the initial 9L or 9L-TK administration. The 9L cell rechallenge inoculum was either 5 ϫ 10 3 , 10 5 , or 10 6 cells. Animals were sacrificed at 2 weeks after rechallenge, and tissues were collected for histology; brain, leg, kidney, spleen, lung, and liver tissues were examined.
I.c. 9L-TK, systemic 9L rechallenge on day 28.
Animals were initially given (day 0) fully transduced 9L-TK cells i.c. (5 ϫ 10
3 ) and treated with daily i.p. GCV between days 14 and 23. Rechallenge occurred on day 28 with parental 9L (either at 5 ϫ 10 3 , 10 5 , or 10 6 cells, n ϭ 3, 5, and 3, respectively) administered i.m. into the right leg. The animals were sacrificed at 2 weeks after rechallenge, and tissues were collected for histology.
I.c. 9L-TK, i.c. 9L rechallenge on day 28.
Animals were given 9L-TK and GCV as described above, but rechallenge with parental 9L cells (5 ϫ 10 3 , n ϭ 4) occurred on day 28 after 9L-TK infusion in contralateral brain; after 2 weeks, animals were sacrificed and tissues were collected.
Systemic 9L-TK, systemic 9L rechallenge on day 28.
Another set of animals (n ϭ 5) was given 9L-TK cells (10 5 ) on day 0 i.m. into the right hind limb. The animals were treated with daily GCV between days 14 and 23. On day 28, animals were rechallenged with parental 9L cells (10 5 ) in the left leg. After 2 weeks, the animals were sacrificed and tissues were collected.
I.c. 9L, transduced in situ with HSV-TK vector and treated with GCV, systemic 9L rechallenge on either day 28 or 60.
In another set of experiments, i.c. 9L tumor (5 ϫ 10 3 ) was established for 1 week, and HSV-TK retroviral particles and GCV were administered as described above. Hind limb rechallenge with parental 9L cells (10 5 ) occurred on either day 60 (n ϭ 6) or day 28 (n ϭ 4) after 9L-TK infusion; 2 weeks later animals were sacrificed and tissues collected.
Histochemistry
Tissue specimens (4-mm sections anterior to the cannulation site and placement of tumor) were placed into Tissue-Tek optimal cutting temperature embedding medium (Miles, Elkhart, Ind) and frozen on dry ice. Frozen brain sections were stored at Ϫ80°C until sectioning. Sections (5 m) were placed onto Superfrost Plus slides (Fisher Scientific, Pittsburgh, Penn), dried overnight, and stained with Harris hematoxylin and eosin. Other tissue specimens (4-mm sections posterior to the cannulation site) were placed into buffered formalin for 1 week before being embedded in paraffin. Sections (5 m) were placed onto slides, dewaxed, and stained with hematoxylin and eosin. 5 
Testing for humoral response
Sera from the gene therapy-treated animals used in the rechallenge experiments (see Table 3 ) were collected at 2 weeks after rechallenge to test for the production of antibodies (Abs) to 9L-TK or TK. The blood, collected by heart puncture, was allowed to clot for 45 minutes at room temperature. Bloods were then centrifuged at 400 ϫ g for 10 minutes, and sera were collected and stored at Ϫ20°C until testing.
Irradiated (5000 rad) 9L or 9L-TK cells (10 5 ) were placed into noncannulated animals using a Hamilton syringe on day 0 (n ϭ 4 each). On day 28 after infusion of tumor, hind limb rechallenge (10 5 ) with parental 9L cells was given. Sera were collected at 2, 3, and 4 weeks after the initial injection of tumor and then at 2, 3, and 4 weeks after rechallenge.
A cell-based enzyme-linked immunosorbent assay (ELISA) using 9L and 9L-TK as targets was performed to detect Ab to 9L or 9L-TK. 9L gliosarcoma cells or Rat-2 Fischer fibroblasts (American Type Culture Collection, Manassas, Va) were seeded in 96-well plates at a density of 5 ϫ 10 3 cells/well in complete medium and incubated at 37°C for 3 days. The monolayers were washed once in PBS and dried upside-down overnight; the plates were sealed with plate sealers (Titertek, Huntsville, Ala) and stored at 4°C until required. The dried cell monolayers were rehydrated, and nonspecific protein binding sites were blocked by incubating the plates in 125 L/well casein acid hydrolysate (Sigma, St. Louis, Mo) for 1 hour at room temperature. Excess blocking buffer was removed, but the wells were not washed. Immediately before use, sera were defrosted at 37°C, diluted as indicated in Ab dilution buffer (PBS supplemented with 0.1% (wt/vol) bovine serum albumin, 0.05% (vol/vol) Tween-20, 1% (wt/vol) human serum albumin, and 2.5% (vol/vol) fetal bovine sera) added to the cells in 50-L volumes, and incubated as described previously. The cells were washed three times with Ab dilution buffer containing 0.1% Tween 20 and incubated with 2.4 g/mL sheep anti-mouse immunoglobulin G-biotin (Sigma) in Ab dilution buffer with Tween 20 for 60 minutes at 37°C. After three washes, the monolayers were incubated with streptavidin-biotin complex conjugated to horseradish peroxidase for 60 minutes at 37°C. After three more washes, the cells were incubated with substrate solution (20 mL 0.1 M citric acid plus 20 mL 0.2 M Na 2 HPO 4 plus 20 mg O-phenylenediamine plus 20 L 30% H 2 O 2 ) for 15-30 minutes at 25°C in the dark. The reaction was stopped by adding 0.18 M H 2 SO 4 , and the absorbance was read at 490 nm.
Ouchterlony immunoprecipitation was also conducted according to a prior protocol. 8, 9 Briefly, rat sera were placed into template wells to run against either 9L or 9L-TK cell lysate using double-width microscope slides coated with 1.4% agarose. After diffusion for 48 hours at 4°C in a moist chamber, nonprecipitating proteins were removed; next, the slides were stained with Crowle's double stain, and finally cleared with 0.3% acetic acid for 5 minutes at room temperature.
RESULTS
Quantitative in vitro assay for bystander effects
An assay was performed to assess the proportion of the tumor burden that was susceptible to GCV-mediated killing (or stasis) versus that due to close contact of the cells and to a gap junction-type phenomenon. Figure 1 shows the observed (solid bars) versus expected (open bars) metabolic activities from admixtures of parental and 100% HSV-TK-transduced 9L cells. The cell mixtures seeded at high density (Fig 1A) , in which bystander effects and primarily GCV killing/stasis would be measured, show that the bystander effect of 9L cells is exceptionally high. Practically all cells were affected when only 5% 9L-TK cells were present in high-density cultures. As little as 1% 9L-TK produced detectable effects, and 2% 9L-TK produced highly significant effects of almost 50%. Bystander effects were also observed with cell admixtures plated at low density ( Fig  1B) , where cell-to-cell contact would be at a minimum. Detectable effects were seen at 2% 9L-TK, became significant at 5%, and became very significant when almost 50% were affected at 10% 9L-TK. Interestingly, at low density a maximum 90% effect occurred, even in 100% 9L-TK culture.
Tumor volumetric analyses of control animals and animals treated with suicide gene therapy at day 26 after infusion of 9L group D) . Highly significant statistical differences exist between these control groups and the experimental in situ HSV-TK retroviral particletransduced and 10-day GCV-treated group (Table 1 , group F) and the positive control group given 9L-TK tumor cells and treated with 10-day GCV (Table 1 , group G). The 10-day regimen of GCV was important in the treatment, as the efficacy of the group given HSV-TK vector with 10 daily administrations of GCV ( Histological examination revealed, on day 26 after 9L infusion, sizable tumors in every animal in groups A-E (Table 1) . Significantly, 4 of 14 animals (29%) given HSV-TK vector and 10-day GCV had no tumor, but an additional 3 (21%) had Ͻ1% tumor volume (percentage responding ϭ 50%). Remarkably, 10 of 19 animals (53%) given fully transduced 9L-TK tumor and 10-day 
9L HSV-TK ϩ 10-day GCV 5.9 Ϯ 1.9 G (n ϭ 19) 9L-TK † 10-day GCV 2.3 Ϯ 1.4
‫ء‬Percent MTV Ϯ SE at day 26 of rats with a 1 week established tumor (5000 9L cell inoculum) that were treated as described previously. Calculations were as described in Materials and Methods. Statistically significant differences were obtained: P Ͻ .0002 between groups A, B, and D, and group G; P Ͻ .0067 between groups A, B, and D and group F; P Ͻ .025 between groups E and F.
†9L-TK is a G418-selected tumor (100% transduced). Group G serves as a positive control. A sham-treated 9L-TK-negative control group was not included in this experiment because our prior work 5 demonstrated that (a) the growth rates of 9L and 9L-TK were identical in vitro, and (b) GCV is toxic to 9L-TK but not to 9L parental cells. GCV had no tumor, and an additional 7 (36%) had Ͻ1% of tumor (percentage responding ϭ 89%). Figure 2A is a Kaplan-Meier survival plot for 1-week established (5000 cell inoculum) 9L tumor-bearing animals given either HSV-TK vector alone or HSV-TK vector and 10-day GCV; the medians are 32 and 58 days, respectively. At day 60 after 9L infusion, the MST Ϯ SE of animals treated with HSV-TK retroviral particles only (given an initial inoculum of 5 ϫ 10 3 9L cells) was 35.0 Ϯ 1.72 days (n ϭ 7) compared with 55.4 Ϯ 1.35 days for the HSV-TK retroviral particle/GCV combination therapy group (n ϭ 16). According to log-rank or Wilcoxon nonparametric analyses, the differences in survival were highly statistically significant (P Ͻ .0001); a total of 6 of 16 animals (38%) receiving the combination therapy were still alive and were treated as censored observations in the statistical analyses. Histologically, the animals showed clean cavities at the instillation site of (Table 1) revealed no statistically significant differences between the shamtreated, the HSV-TK only treated, and the GCV only treated groups, only one negative control group (HSV-TK only) was chosen for the survival experiment. B: The individual animal weights over the treatment and follow-up period indicate that there is little toxicity associated with treatment and that the animals thrive until they begin to experience the morbidity associated with tumor progression. The mean group weights plotted over time indicated that the retroviral particle administration was not toxic; however, the dose of Dex used was deleterious in conjunction with tumor progression and GCV administration.
Survival of HSV-TK vector-treated animals versus those treated with HSV-TK vector and GCV
tumor; one had a small sterile abscess formation. The cavities had very little lymphocytic infiltrate, unlike those of the day 26 sacrificed counterparts, which actually showed significant numbers of CD4 ϩ and CD8 ϩ cells. 5 In addition, to assess the toxicity of the treatment, the weights of all animals were plotted over time (Fig 2B) . According to this parameter, retroviral particle administration (days 7-12) is not toxic and GCV administration (days 14 -23) is not toxic or only slightly so; the latter is harder to determine based on the appearance of morbidity associated with tumor progression being close to the timing of GCV administration.
Survival analyses of animals with increased tumor burden treated by suicide gene therapy with or without high-dose steroids In another experiment, animals were given double the tumor cell inoculum (10,000 9L or 9L-TK tumor cells) compared with the prior survival experiment. Treatment commenced after 1 week. Several animal groups were also placed on large daily doses of oral Dex. The survival of these animals in a Kaplan-Meier plot is depicted ( Fig  3A) along with the mean group weights of the animals over time (Fig 3B) . Table 2 gives the MSTs and the statistical significance of all groups. Although the group treated with HSV-TK vector, GCV, and Dex achieved statistical significance to the negative HSV-TK vector alone control group, it was not significantly different from the experimental group given HSV-TK vector and GCV. Not surprisingly, the two positive control groups given 9L-TK-transduced tumor with or without Dex exhibited increased survival compared with those groups given 9L tumor that required in situ transduction with HSV-TK vector. There was no statistical difference (P ϭ .057) between the positive control group given Dex versus the same group not given steroid, although at day 60 the group not receiving Dex had 55% surviving compared with only 10% surviving for those receiving Dex (Fig 3A) . In contrast with the first experiment, in which the treatment was highly efficacious in animals started with a lower tumor inoculum (Fig 2A) , the larger in situ-transduced 9L tumors were not effectively treated without Dex.
Mean group weights plotted over time (Fig 3B) demonstrate that little toxicity was associated with retroviral particle administration (days [7] [8] [9] [10] [11] [12] . Dex administration at the dose used (days 6 -20, tapered through day 26) did cause weight loss, which was likely exacerbated by increased tumor burden and GCV administration (days 14 -23) . Because the animals exhibited a significant weight drop, we began tapering the Dex on day 20. Animals were off steroid by day 26, and a rebound in the weights of the two groups receiving steroid occurred. Any animals that thrived past day 30 were those with 9L-TK tumor that were treated with GCV, including those that did and did not receive Dex. Table 3 , the immunogenicity of i.c. 9L-TK followed by GCV treatment is enough to provide some degree of protection when animals are rechallenged systemically with parental 9L (i.c./sys). The degree of protection can be correlated with the total number of cells used for hind limb rechallenge. Tumor was not evident in the hind limbs of 100% of the animals given the smallest rechallenge inoculum of 5 ϫ 10 3 cells. As the rechallenge inoculum increased to 10 6 cells, the ability to resist tumor growth decreased. Not surprisingly, 100% of the animals given an initial exposure to 9L-TK in one hind limb, given GCV, and subsequently rechallenged in the opposite hind limb (sys/sys) were able to resist rechallenge at an inoculum of 10 5 9L cells. Also, 50% of the animals given an initial i.c. exposure to 9L-TK, treated with GCV, and subsequently rechallenged in contralateral brain with 9L (i.c./i.c.) resisted rechallenge. In two animals with microscopically detectable 9L tumor (parenchymal in one and leptomeningeal in the other), the tumor was Ͻ0.1% of 9L-TK 10-day GCV 53.7 Ϯ 3.2 E (n ϭ 10) 9L-TK 10-day GCV ϩ Dex 45.4 Ϯ 3.7
Analyses of rechallenged animals I.c. or systemic 9L-TK with 10-day GCV treatment, systemic 9L rechallenge on day 28. As shown in
‫ء‬MST Ϯ SE at day 60 of rats with a 1 week established tumor (10 4 cell inoculum) that were treated as described previously. Statistically significant differences were obtained: P Ͻ .0001 between paired groups A, D; A, E; B, D; B, E; and C, D; P Ͻ .0018 between paired group C, E; P Ͻ .03 between paired group A, C. Similar groups with and without Dex did not reach statistical significance; P Ͻ .08 for B, C; P Ͻ .057 for D, E. ‫ء‬Animals were either (a) given 9L-TK i.c. or systemically (sys), (hind limb) followed by a 10-day regimen of GCV (days 12-23 posttumor), or (b) given 9L tumor, which was transduced in situ with six daily i.c. infusions of HSV-TK retroviral particles (6 ϫ 10 the total brain volume. The tumor cells from both were negative for TK by immunohistochemistry. All other organs examined had no tumor. Table 3 , six animals surviving treatment with in situ-administered HSV-TK retroviral particles and GCV were rechallenged on day 60 with parental 9L cells (10 5 ) given in the right leg. At 2 weeks after rechallenge, histological analyses of the hind limb tissue showed that 100% of the animals resisted rechallenge; no viable tumor was evident.
I.c. 9L/in situ transduction with HSV-TK vector/10-day GCV treatment, systemic 9L rechallenge on days 28 or 60 (i.c./sys). Again, as shown in
The leg muscle rechallenge of 10 5 tumor cells that were given at day 28 and allowed to grow for 14 days showed absence of tumor in 75% of the animals. One animal had palpable tumor intercalated in its leg muscle that was viable and mitotically active. All other tissues, kidneys, spleens, livers, and lungs were free of tumor. These results are fairly comparable with the 80% resistant population obtained with i.c. 9L-TK/GCV-treated rats given systemic rechallenge on day 28 with 9L.
Overall, the results indicate that prior exposure of the animal to either 9L or 9L-TK and treatment using suicide gene therapy makes them relatively resistant to rechallenge, suggesting that a cell-mediated immune response is involved in containing the second tumor dose. The memory to 9L tumor in these gene therapytreated animals is still evident at 60 days after 9L infusion.
Assessment of the humoral response to HSV-TK vector and GCV therapy A humoral response to either 9L or 9L-TK was assessed either using (a) a cell-based ELISA or by (b) immunoprecipitation using standard Ouchterlony plates with sera from animals given either 9L plus HSV-TK retroviral particles or 9L-TK; both sets of animals were treated with GCV. Sera from all animals listed in Table  3 were analyzed by the cell-based ELISA. The results showed either a nonspecific reaction or a nondemonstrable reaction.
The immunoprecipitation data correlate with the ELISA. We conclude that in the samples collected 2 weeks after rechallenge, Ab is not detected; humoral immunity does not appear to be engendered in a major way in this system.
DISCUSSION
In prior work, 5 we demonstrated that established 9L tumors could be successfully treated with HSV-TK retroviral particle gene transfer and systemic GCV. By contrast, animals receiving either reagent alone displayed progressive lethal tumor growth. Interestingly, regressing tumors were heavily infiltrated with CD4 ϩ and CD8
ϩ cells, suggesting a cellular immune response to syngeneic brain tumors treated by gene therapy. 5 In this paper, tumor volumetric studies demonstrate that 89% of fully transduced 9L-TK tumors (5000 cell inoculum) treated with GCV responded to treatment. In addition, 50% of those animals with 1-week established 9L tumors (5000 cell inoculum) responded when treated in situ with HSV-TK retroviral particles followed by GCV administration; survival studies of the like experimental group showed that 38% of animals were alive at 60 days.
Despite the low in situ transduction of retroviral particles in the 9L gliosarcoma model, 5 efficacy in tumor volumetric (Table 1 ) and survival studies (Fig 2A) is evident in rats with lower tumor burden. Higher tumor burdens compromise the efficacy of this adjuvant treatment (Fig 3A) . To obtain the best clinical results, these data indicate the necessity of surgical resection of tumor before gene therapy is used or the use of this adjuvant treatment before recurrence and when tumor burden is minimal.
For suicide gene therapy to be effective, transduction of every tumor cell is not required due to bystander effects. The efficacy observed, which is beyond that which would occur from the expected activity as calculated from in situ transduction rate, has been termed the bystander effect. 10 -17 Our observed in vitro GCV and bystander kill of 9L/9L-TK cell mixtures (Fig 1) convincingly presents the power of the bystander effect in vitro, especially when cells are in close contact. In vivo, appropriate delivery and distribution of the transduced cells are important to overall efficacy, as pointed out in several studies, 18, 19 but it is encouraging that an in situ ␤-galactosidase retroviral particle-transduced tumor was noted in perivascular space, where infiltrating tumors are often found. 5 Others have observed both in vitro and in vivo that a fraction of the cells engineered to express the HSV-TK gene survive GCV and undergo cell division. 20 The finding that not all cells in 100% transduced cultures were killed (Fig 1) also suggests that a small percentage of cells may not make enough TK protein to be killed directly by GCV. The resistant population of tumor cells evidenced in the outgrowth of microscopic amounts of tumor in animals that seemingly were cured by suicide gene therapy is likely reflective of low TK-expressing cells that were not susceptible to the GCV. This may be a simplistic interpretation of the data, because a recent report 21 indicates that the resistant population of 9L/ HSV-TK cells treated with GCV actually expressed less class I major histocompatibility protein, resulting in lesser lymphocytic infiltrates in vivo.
To contain the costs of this therapy clinically, we investigated a shorter, 5-day period of GCV administration. Our studies (Table 1 ) indicated the necessity of prolonging the period of GCV administration to 10 days. We and others reporting efficacy with suicide gene therapy have typically administered GCV for 10 days to 2 weeks. 5, [21] [22] [23] One report shows that the efficacies of 7-day versus 14-day GCV (50 mg/kg) administration in suicide gene therapy groups were not statistically different. 24 Because the proliferation rates of human tumors are expectedly lower than murine tumors, clinically, a longer course of GCV would be indicated to achieve maximum efficacy.
In histologically cured animals, the additional antitumor effects are probably T cell-mediated, as demonstrated by (a) immunohistochemical analysis showing CD4 ϩ and CD8 ϩ lymphocytic infiltrates in HSV-TK vector/GCV-treated animals at day 26, 5 (b) the resistance to tumor rechallenge seen in gene therapy-cured animals (Table 3) , and (c) the higher cure rate obtained at day 60 (38%) compared with day 26 (29%). The latter reflects therapeutic effects taking place long after complete clearance of GCV from the body; these effects are most likely cell-mediated, because we were unable to detect a humoral response.
Dex, an immunosuppressive agent, controls edema in brain tumor patients. 25, 26 Dex inhibits interleukin-2 synthesis in T lymphocytes by interfering with nuclear factor activator protein-1 binding to the interleukin-2 promoter and also with calcineurin-dependent pathways for T-cell activation. 27 Because suicide gene therapy is touted to have bystander immune system effects, we wanted to ascertain whether a fairly high dose of Dex would abrogate the efficacy of suicide gene therapy by interfering with immune-mediated function(s). This information ultimately would impact on patient eligibility for suicide gene therapy clinical trials involving retroviral particles. We found that there were no demonstrable statistical effects on efficacy (Fig 3A) , as others have found for this type of therapy. 22 In effect, our experimental design tested effects of Dex (given on days 6 -26) during gene therapy treatment (days 7-23), but was not maintained for very long after the treatment ended. As our data indicate, an increase in efficacy was noted between days 26 and 60. Thus, even if Dex depressed cell-mediated effects, they still could have initiated after Dex administration ceased (Fig 3A) .
Interestingly, in another study, Dex was tested to determine whether an enhancement of efficacy could be achieved by eliminating effects of the immune system on xenogenic packaging cell lines; there were no differences in the survival of groups that did or did not receive Dex. 28 Our dose of steroid was chosen based on its prior use by another group testing suicide gene therapy with packaging cell lines. 28, 29 This dose roughly mimicked a human dose of 16 mg of Dex per day. We observed more than a 30% decrease in the mean group body weight of animal groups receiving Dex. The animals exhibited symptoms consistent with a diabetic state; they were active and thirsty. From prior study, 2 we knew that a smaller dose abrogated adrenocorticotrophic hormone synthesis. We had intended to maintain the rats on steroid until day 28; however, at day 20 we made a decision to begin a taper such that by day 26 the rats were totally weaned. In effect, the two groups of animals that were given steroids exhibited an increase in mean group weights after discontinuation. Animals alive at day 42 had returned to or exceeded their weights at the start of the experiment (Fig 3B) .
Tumor eradication by HSV-TK vector/GCV treatment confers lasting tumor immunity. 21,24,29 -32 Because rat brain tumors are thought to be more immunogenic than human brain tumors, 33, 34 it is not known whether the endogenous immune response seen is a direct result of the gene therapy treatment, the immunogenicity of the tumor, or both. However, we did not see any evidence for immune involvement in animals bearing naturally necrotic tumor masses; consequently, invoking an immune reaction based solely on 9L cell death is not achievable. Furthermore, GCV-mediated cell death could release 9L components, which could help to immunize the animals against further tumor transplantation. We looked at both humoral as well as cellmediated 5 components at work in this experimental system. The humoral response at the timepoint we analyzed was largely lacking to 9L or to 9L-TK. Our rechallenge experiments (Table 3) indicate that animals treated by suicide gene therapy generate a host immune response such that some or complete resistance to 9L tumor is engendered when animals are later rechallenged with this tumor. Overall, our data indicate that a significant bystander effect and cell-mediated response both play roles in suicide gene therapy with HSV-TK retroviral particles. Further experimentation is needed to elucidate the role of particular T-cell subsets and cytokine networks in this process, but combination therapies using both gene transfer and immunostimulatory components could be effective in treating primary brain tumors. 35 
